RT Journal Article
SR Electronic
T1 Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 949
OP 954
VO 34
IS 2
A1 KISS, IGOR
A1 BORTLICEK, ZBYNEK
A1 MELICHAR, BOHUSLAV
A1 POPRACH, ALEXANDR
A1 HALAMKOVA, JANA
A1 VYZULA, ROSTISLAV
A1 DUSEK, LADISLAV
A1 BUCHLER, TOMAS
YR 2014
UL http://ar.iiarjournals.org/content/34/2/949.abstract
AB The aim of the present study was to describe treatment outcomes for bevacizumab in combination with chemotherapy based on data from the Czech registry of targeted therapies for metastatic colorectal cancer (mCRC). Patients and Methods: In total, 4,487 patients with mCRC who received bevacizumab combined with chemotherapy in first line (n=3,990, 88.9%), second line (n=386, 8.6%), or third/higher line (n=111, 2.5%) had evaluable data and were included in the present retrospective analysis. Results: The median progression-free survival (PFS) was 11.3 months (95% conficence interval [CI]=11.0-11.7 months), 9.5 months (95% CI=8.2-10.9 months), and 7.3 months (95% CI=5.9-8.7 months; p<0.001), and the median overall survival from the start of bevacizumab-containing therapy was 28.4 months (95% CI=27.1-29.8 months), 25.9 months (95% CI=19.4-32.4 months), and 15.0 months (95% CI=10.7-19.3 months; p<0.001), respectively. Conclusion: The data describe efficacy of bevacizumab with chemotherapy for different treatment lines in a large patient cohort.